-
Glucagon/GLP-1 receptor dual agonist demonstrates efficacy for obesity and MASLD
Matthias H. Tschöp, MD, and other researchers detailed phase 3 results of SYNCHRONIZE-1 and SYNCHRONIZE-MASLD showing that survodutide leads to significant weight loss, reduction in liver fat, and other health improvements.
-
Diabetes Journal symposium to explore non-classical complications of diabetes
Norbert Stefan, MD, PhD, and three other panelists will present the latest findings on how complications such as metabolic dysfunction-associated steatotic liver disease (MASLD), infections, cancer, and diastolic dysfunction are impacting individuals living with diabetes.
-
Session to provide updates on MASLD, lipoprotein biology, and CV risk
Panelists will discuss an underexplored nexus of metabolic dysfunction in diabetes on the final day of the 2026 Scientific Sessions. Scott Summers, PhD, will explore the role of ceramides in metabolic dysfunction-associated steatotic liver disease and cardiovascular risk. Other topics include cholesterol, clot lysis, and thrombosis.